Development and validation of selective novel small molecule therapeutics for Parkinson's Disease

Parkinson’s disease is the second most common neurodegenerative disorder, affecting a million people or more in America alone. Many lines of evidence point to a role of inflammation and the immune system in triggering neurodegeneration and disease progression.

This team will use their Neuroscience:Translate award to develop small-molecule therapeutics with immunomodulatory properties linked to Parkinson’s disease and test their potentially therapeutic effects in cell cultures and animal models of the disease.